相关实验视频
Updated: Jan 8, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
875
托皮拉对严重肥胖的幼儿体重状况的影响
Mostafa Salama1,2, Doha Hassan2, Siobhan Pittock1,2
1Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Journal of the Endocrine Society
|December 15, 2025
概括
在患有严重肥胖症的幼儿中,托皮拉显著降低了体重指数 (BMI). 这种药物对儿童肥胖症的管理有前途,特别是在患有下丘脑参与的情况下.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 药理学 药理学是指药理学的学科.
- 肥胖医学 肥胖医学
背景情况:
- 对于治疗早期严重的儿童肥胖症,药理选择有限.
- 严重的儿童肥胖症对健康构成重大风险,需要有效的干预措施.
研究的目的:
- 评估托皮拉在降低体重指数 (BMI) 和改善严重肥胖的幼儿心脏代谢参数方面的疗效.
- 评估托皮拉在肥胖儿童的效果,包括那些患有下丘脑病因的儿童.
主要方法:
- 一个追溯的案例系列,涉及14名12岁以下的儿童,患有严重肥胖症,接受了托皮拉治疗.
- 在治疗前和治疗期间分析人体统计数据 (BMI百分位数,BMIz-score) 和心脏代谢标志物.
主要成果:
- 托皮拉治疗导致95%百分位数的BMI%中位数下降8% (P = .042) 和BMIz-score下降0.37 (P = .028).
- 14名儿童中有11名经历了BMI降低;一个患有下丘脑肥胖症的儿童在24个月内BMI%显著下降了35个百分点.
- 没有观察到心脏代谢标志物或线性生长的显著变化.
结论:
- 托皮拉单疗法在患有严重肥胖的幼儿中显著降低了BMI,包括那些患有下丘脑肥胖症的幼儿.
- 需要进一步的前性随机对照试验来确认儿童肥胖管理的长期疗效和安全性.
相关概念视频
Drug Dosing: Obese Patients
198
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
198
Pharmacokinetics in Pediatric Patients: Drug Metabolism
174
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
174
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
159
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
159
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
221
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
221
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
229
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
229
Pharmacokinetics in Pediatric Patients: Drug Distribution
240
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
240

